Fiona Simpkins, M.D.
Hilarie L. and Mitchell L. Morgan President's Distinguished Professor in Women's Health
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Pennsylvania Hospital, Philadelphia, PA
Active Staff, Gynecologic Oncology, Department of Ob/Gyn, Chester County Hospital, West Chester, PA
Director of Clinical & Translational Gynecologic Oncology Research, Penn Medicine Health System
Department: Obstetrics and Gynecology
Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Permanent linkB.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
Selected Publications
Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A.: Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace. Int J Radiat Oncol Biol Phys. (IF = 6.5) Jun 2025.Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM: Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. Am J Obstet Gynecol. (Impact factor 8) Apr 2025.
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nature Communications (Impact factor 17) Apr 2025.
Fiona Simpkins, Alexandra Leary, Lyndsay Willmott, Bradley J. Monk, Jean-Sébastien Frenel, David C. Starks, Meena Okera, Angeles Alvarez Secord, David M. O’Malley, Lainie Martin, Kaissa Ouali, Martin K. Oehler, Jeffrey C. Goh, Brian M. Slomovitz, Peter C. Lim, Catherine M. Shannon, Robert Neff, Doris Kim, Hailun Li, Danielle Jandial, Floor J. Backes : Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066) Gynecology Oncology; plenary, SGO Annual Meeting, March 2025 April 2025.
Erin George, Lakeisha Mulugeta-Gordon, Emily M Ko, Sharon Wu, Joanne Xiu, Nathaniel Jones, Premal H Thaker, Thomas J Herzog, Eric J Brown, Dineo Khabele, Fiona Simpkins: Impact of CCNE1 Amplification on Molecular Signatures and Patient Outcomes in High Grade Serous Ovarian and Endometrial Cancer. Gynecology Oncology; plenary, SGO Annual Meeting, March 2025 April 2025.
Smith AJ, Pancoe S, Lynch MP, Wachlin M, Powell K, Hinkle SN, Koelper NC, Doherty M, Bekelman JE, Simpkins F, Ko EM: Rideshare services for transportation assistance in gynecologic oncology: a quality improvement study. BMC Health Serv Res Feb 2025.
Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, Rames MJ, Kim S, Guo X, Jameson N, de Jong PR, Yea S, Harford L, Li J, Mathews CA, Doroshow DB, Charles VJ, Kim D, Fischer K, Samatar AA, Jubb A, Bunker KD, Blackwell K, Simpkins F, Meric-Bernstam F, Mills GB, Harismendy O, Ma J, Lackner MR: Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ Precis Oncol (Impact Factor 8) Jan 2025.
Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Taylor RN, Barnicle A, Munley JY, Aghajanian C: Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer (IF = 5) Jan 2025.
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL: [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. J Nucl Med (IF= 9) Jan 2025.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS: Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. Genome Medicine (Impact Factor 12) Dec 2024.